Generic Name and Formulations:
Azithromycin 1%; oph. soln; contains benzalkonium chloride.
Indications for AZASITE:
Susceptible bacterial conjunctivitis.
Adults and Children:
<1yr: not established. ≥1yr: 1 drop in affected eye(s) twice daily (8–12hrs apart) for 2 days then once daily for the next 5 days.
For topical ophthalmic use only. Discontinue if superinfection or hypersensitivity occurs. Remove contact lenses during therapy. Pregnancy (Cat.B). Nursing mothers.
Eye irritation; blurred vision, burning/pain, contact dermatitis, corneal erosion, dry eye, itching, ocular discharge.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- Finding Clinical Trials in Cancer
- Adding Nintedanib Did Not Improve Survival in Lung Cancer Subtype
- The Identification of a Potential Early Plasma Biomarker for Kidney Cancer
- Pembrolizumab Plus Chemotherapy Extended Survival Longer Than Chemotherapy Alone: Study
- Combining Chemotherapy With Checkpoint Inhibitors Extends Overall Survival in ES-SCLC
- In a Head-to-Head Battle, Brigatinib Appears to Best Crizotinib